Quality of Life Decline after HF Hospitalization: Entresto vs. Enalapril

The PARADIGM-HF trial is the largest clinical trial ever conducted in heart failure
The PARADIGM-HF trial is the largest clinical trial ever conducted in heart failure

New research presented at the Heart Failure Society of America (HFSA)'s 20th Annual Scientific Meeting further support the clinical benefits of Entresto based on findings from PARADIGM-HF, the largest clinical trial conducted in heart failure (HF).

Data from the post-hoc analysis showed that the decline in health-related quality of life (HRQL) scores associated with a HF hospitalization among patients taking Entresto(sacubitril/valsartan; Novartis) was lower vs. patients taking enalapril, an ACE inhibitor. The analysis included 6,981 patients in PARADIGM-HF that completed a Kansas City Cardiomyopathy Questionnaire (KCCQ) to measure HRQL at baseline and at 8 months; a total of 305 patients were hospitalized for HF during the 8 months. Among the patients hospitalized for HF, those treated with Entresto had lower decline in HRQL (approximately 50%) vs. those taking enalapril (5.11 point decline vs. 10.77 point decline in KCCQ summary score, respectively; P=0.003).  

Related Articles

In PARADIGM-HF, the HRQL declined less in patients treated with Entresto than those treated with enalapril at 8 months of treatment (2.99 point decline vs. 4.63 point decline; P=0.001). 

Data from a second post-hoc analysis in the overall study population showed an association between clinically meaningful worsening in HRQL scores (≥5 point decrease in the KCCQ clinical summary score) after 4 months of treatment and increased risk of worse clinical outcomes, including cardiovascular (CV) death and HF hospitalization. The analysis included 7,155 patients who completed a KCCQ at baseline and at 4 months of treatment. Patients with a clinically meaningful worsening in HRQL had a 24% higher risk of CV death (P=0.009) or 28% higher risk of HF hospitalization (P=0.004). 

Entresto combines sacubitril, a neprilysin inhibitor, and valsartan, an angiotensin II receptor blocker. It is indicated to reduce the risk of cardiovascular death and hospitalization for heart failure in patients with chronic heart failure (NYHA Class II–IV) and reduced ejection fraction. It is available as 24mg/26mg, 49mg/51mg, and 97mg/103mg strength tablets. 

For more information call (800) 693-9993 or visit Entresto.com.

Loading links....